The clinical problem

For too many people the first sign of cardiovascular disease is the event itself. Yet the underlying process develops silently over decades, and standard risk scores often miss people who are genuinely at risk — particularly the young and the seemingly healthy.

The UroLongevity approach

This is one of the most concrete, evidence-grounded areas of the practice. Modern cardiovascular early detection can identify risk many years before symptoms — through measures such as coronary artery calcium (CAC) scoring and advanced markers including ApoB and lipoprotein(a). The point is to find risk while there is still a long runway to act on it.

◆ Dr. Shusterman’s take

If I could have every patient test one thing they have probably never been offered, it would be lipoprotein(a). It is largely genetic, it meaningfully changes the risk picture, and most people carry their number their whole life without ever knowing it.

What’s involved

At a high level, evaluation and intervention may include:

  • Advanced lipid analysis — beyond standard cholesterol, including ApoB
  • Lipoprotein(a) — a powerful, largely genetic risk marker most people are never tested for
  • CAC scoring where appropriate — a direct look at calcified coronary plaque
  • Inflammatory and metabolic markers tied to cardiovascular risk
  • An individualized risk-reduction plan — matched to what the measurements actually show
On dosing Specific dosing and protocols are individualized to your clinical picture and decided in consultation. They are not published here, because one-size guidance is not good medicine.

Honest expectations

Early detection cannot guarantee you will never have cardiovascular disease. What it can do is move the knowledge years earlier — into a window where lifestyle, risk-factor management, and, where indicated, medication have the most leverage. Knowing early is the advantage.